« Return to News | CROs/Service Providers

Algorithme Gets 240 Bed Phase I Unit from BASi

Thursday, July 10, 2008 02:44 PM

Bioanalytical Systems (BASi) sold its Baltimore-based clinical pharmacology research unit to Montreal, Canada-based phase I/bioequivalence CRO Algorithme. BASi sold the 68,000-square-foot, 240-bed unit for $850,000 in cash. Since it is BASi’s only early phase research facility, BASi is exiting the phase I first-in-human clinical trials market. The company is primarily a preclinical, bioanalytical and immuno-assay services firm. It also manufactures specialized equipment for liquid chromatography, in vivo sampling, veterinary medicine and electrochemistry.

According to Algorithme, the 10-year-old company is the largest privately held Québec-owned organization specializing in research services for the pharmaceutical industry. With 400 employees, it maintains four offices in Montreal, including main headquarters and laboratory, a 16,000-square-foot, 80-bed clinic, a medical screening center and now the new BASi unit. The company stated it conducts more than 200 studies per year and reported sales of over $32 million in 2005.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.